9 C.F.R. § 113.50
Ingredients of biological products
All ingredients used in a licensed biological product shall meet accepted standards of purity and quality; shall be sufficiently nontoxic so that the amount present in the recommended dose of the product shall not be toxic to the recipient; and in the combinations used shall not denature the specific substances in the product below the minimum acceptable potency within the dating period when stored at the recommended temperature.
Notes of Decisions
Cited in 2
cases, 1998–1998 · leading case: prod.liab.rep. (Cch) P 15,330 Richard Symens Joyce Symens v. Smithkline Beecham Corp., Ivan Sjovall v. Smithkline Beecham Corp., 152 F.3d 1050 (8th Cir. 1998).
prod.liab.rep. (Cch) P 15,330 Richard Symens Joyce Symens v. Smithkline Beecham Corp., Ivan Sjovall v. Smithkline Beecham Corp., 152 F.3d 1050 (8th Cir. 1998). “See 9 C.F.R. §§ 113.50 -.55. APHIS-mandated testing procedures ensure the “purity, safety, potency, and efficacy” of the vaccine.”
Richard Symens v. Smithkline Beecham (8th Cir. 1998). “See 9 C.F.R. §§ 113.50 -.55. APHIS-mandated testing procedures ensure the “purity, safety, potency, and efficacy” of the vaccine.”
Annotations are extracted automatically from the opinions in the
Syfert caselaw corpus and ranked by authority, recency, and
treatment. Dots show Syfertize treatment of the citing case itself.